As a consequence, the latest American Diabetes Association (ADA) guidelines recommend the use of SGLT2 inhibitors in patients with T2D and HF, especially HFrEF, regardless of the patient’s diabetes status and prior use of metformin [13]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.